Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Mise à jour : Il y a 4 ans
Référence : NCT00126893

Femme et Homme

Extrait

This is a single center Phase 1 study to evaluate the safety, pharmacokinetics and pharmacodynamics of CC-401 in subjects with refractory acute myelogenous leukemia.


Critère d'inclusion

  • Myeloid leukemia

Liens